Atai Beckley (ATAI) Competitors

$4.01 -0.03 (-0.74%)

Closing price 05/15/2026 04:00 PM Eastern

Extended Trading

$4.01 0.00 (-0.02%)

As of 05/15/2026 07:55 PM Eastern

ATAI vs. CNTA, MIRM, CGON, RYTM, and GRFS

Should you buy Atai Beckley stock or one of its competitors? MarketBeat compares Atai Beckley with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Atai Beckley include Centessa Pharmaceuticals (CNTA), Mirum Pharmaceuticals (MIRM), CG Oncology (CGON), Rhythm Pharmaceuticals (RYTM), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Atai Beckley compare to Centessa Pharmaceuticals?

Centessa Pharmaceuticals (NASDAQ:CNTA) and Atai Beckley (NASDAQ:ATAI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations, profitability and media sentiment.

In the previous week, Atai Beckley had 2 more articles in the media than Centessa Pharmaceuticals. MarketBeat recorded 7 mentions for Atai Beckley and 5 mentions for Centessa Pharmaceuticals. Atai Beckley's average media sentiment score of 1.25 beat Centessa Pharmaceuticals' score of 0.41 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Centessa Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atai Beckley	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Centessa Pharmaceuticals has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Centessa Pharmaceuticals' return on equity of -60.37% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Centessa Pharmaceuticals has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.59, meaning that its stock price is 59% more volatile than the broader market.

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 26.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Centessa Pharmaceuticals has higher revenue and earnings than Atai Beckley. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Centessa Pharmaceuticals	$15M	393.87	-$197.53M	-$1.79	N/A
Atai Beckley	$3.49M	423.27	-$660.05M	-$2.23	N/A

Centessa Pharmaceuticals currently has a consensus target price of $40.70, suggesting a potential upside of 2.80%. Atai Beckley has a consensus target price of $14.63, suggesting a potential upside of 264.71%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts clearly believe Atai Beckley is more favorable than Centessa Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Atai Beckley beats Centessa Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Mirum Pharmaceuticals?

Atai Beckley (NASDAQ:ATAI) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Mirum Pharmaceuticals has higher revenue and earnings than Atai Beckley. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$3.49M	423.27	-$660.05M	-$2.23	N/A
Mirum Pharmaceuticals	$521.31M	11.95	-$23.36M	-$13.61	N/A

In the previous week, Mirum Pharmaceuticals had 14 more articles in the media than Atai Beckley. MarketBeat recorded 21 mentions for Mirum Pharmaceuticals and 7 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 1.25 beat Mirum Pharmaceuticals' score of 0.62 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mirum Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Atai Beckley currently has a consensus price target of $14.63, indicating a potential upside of 264.71%. Mirum Pharmaceuticals has a consensus price target of $136.42, indicating a potential upside of 33.51%. Given Atai Beckley's higher possible upside, equities research analysts plainly believe Atai Beckley is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.93

28.4% of Atai Beckley shares are held by institutional investors. 26.8% of Atai Beckley shares are held by company insiders. Comparatively, 14.4% of Mirum Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Mirum Pharmaceuticals has a net margin of -140.24% compared to Atai Beckley's net margin of -19,019.44%. Mirum Pharmaceuticals' return on equity of -11.28% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%

Atai Beckley has a beta of 1.59, indicating that its share price is 59% more volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Summary

Atai Beckley beats Mirum Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to CG Oncology?

Atai Beckley (NASDAQ:ATAI) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

CG Oncology has higher revenue and earnings than Atai Beckley. CG Oncology is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$3.49M	423.27	-$660.05M	-$2.23	N/A
CG Oncology	$4.04M	1,461.19	-$160.99M	-$2.33	N/A

In the previous week, CG Oncology had 27 more articles in the media than Atai Beckley. MarketBeat recorded 34 mentions for CG Oncology and 7 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 1.25 beat CG Oncology's score of 0.16 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	7 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

CG Oncology has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. CG Oncology's return on equity of -23.33% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
CG Oncology	N/A	-23.33%	-22.24%

Atai Beckley currently has a consensus price target of $14.63, indicating a potential upside of 264.71%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 22.11%. Given Atai Beckley's stronger consensus rating and higher probable upside, research analysts plainly believe Atai Beckley is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 26.8% of Atai Beckley shares are owned by insiders. Comparatively, 4.8% of CG Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Atai Beckley has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, CG Oncology has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Summary

Atai Beckley beats CG Oncology on 9 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Atai Beckley (NASDAQ:ATAI) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Atai Beckley. MarketBeat recorded 17 mentions for Rhythm Pharmaceuticals and 7 mentions for Atai Beckley. Atai Beckley's average media sentiment score of 1.25 beat Rhythm Pharmaceuticals' score of -0.26 indicating that Atai Beckley is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rhythm Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Rhythm Pharmaceuticals has a net margin of -93.33% compared to Atai Beckley's net margin of -19,019.44%. Atai Beckley's return on equity of -89.79% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Rhythm Pharmaceuticals	-93.33%	-203.25%	-44.99%

Atai Beckley currently has a consensus price target of $14.63, indicating a potential upside of 264.71%. Rhythm Pharmaceuticals has a consensus price target of $131.81, indicating a potential upside of 45.62%. Given Atai Beckley's stronger consensus rating and higher probable upside, research analysts plainly believe Atai Beckley is more favorable than Rhythm Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.84

Rhythm Pharmaceuticals has higher revenue and earnings than Atai Beckley. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$3.49M	423.27	-$660.05M	-$2.23	N/A
Rhythm Pharmaceuticals	$189.76M	32.69	-$196.54M	-$3.13	N/A

Atai Beckley has a beta of 1.59, indicating that its stock price is 59% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

28.4% of Atai Beckley shares are owned by institutional investors. 26.8% of Atai Beckley shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Atai Beckley beats Rhythm Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Atai Beckley compare to Grifols?

Grifols (NASDAQ:GRFS) and Atai Beckley (NASDAQ:ATAI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation.

In the previous week, Atai Beckley had 2 more articles in the media than Grifols. MarketBeat recorded 7 mentions for Atai Beckley and 5 mentions for Grifols. Atai Beckley's average media sentiment score of 1.25 beat Grifols' score of 1.16 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a net margin of 5.54% compared to Atai Beckley's net margin of -19,019.44%. Grifols' return on equity of 6.21% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Grifols presently has a consensus price target of $10.00, indicating a potential upside of 30.55%. Atai Beckley has a consensus price target of $14.63, indicating a potential upside of 264.71%. Given Atai Beckley's stronger consensus rating and higher possible upside, analysts plainly believe Atai Beckley is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Grifols has higher revenue and earnings than Atai Beckley. Atai Beckley is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	40.32
Atai Beckley	$3.49M	423.27	-$660.05M	-$2.23	N/A

Grifols has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

28.4% of Atai Beckley shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Comparatively, 26.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Atai Beckley beats Grifols on 10 of the 17 factors compared between the two stocks.

Get Atai Beckley News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATAI vs. The Competition

Export

Metric	Atai Beckley	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.49B	$5.57B	$6.33B	$12.47B
Dividend Yield	N/A	1.52%	2.80%	5.28%
P/E Ratio	-1.80	33.85	20.31	25.25
Price / Sales	423.27	22.60	547.49	77.32
Price / Cash	N/A	16.52	43.04	56.04
Price / Book	5.81	3.13	9.83	6.91
Net Income	-$660.05M	$218.81M	$3.56B	$334.11M
7 Day Performance	-0.50%	-1.06%	0.27%	0.01%
1 Month Performance	-1.96%	1.62%	-1.29%	1.17%
1 Year Performance	143.03%	13.72%	33.63%	30.68%

Atai Beckley Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATAI Atai Beckley	4.0664 of 5 stars	$4.01 -0.7%	$14.63 +264.7%	+146.0%	$1.49B	$3.49M	N/A	80	Positive News Earnings Report Analyst Upgrade
CNTA Centessa Pharmaceuticals	2.0687 of 5 stars	$39.70 +0.3%	$40.70 +2.5%	+214.5%	$5.90B	$15M	N/A	200
MIRM Mirum Pharmaceuticals	2.5344 of 5 stars	$105.79 +9.6%	$123.83 +17.1%	+125.7%	$5.89B	$521.31M	N/A	140	Analyst Revision High Trading Volume
CGON CG Oncology	2.463 of 5 stars	$67.70 +2.2%	$79.55 +17.5%	+164.0%	$5.83B	$4.04M	N/A	61	Earnings Report Analyst Forecast Analyst Revision
RYTM Rhythm Pharmaceuticals	2.1127 of 5 stars	$85.58 +4.6%	$131.13 +53.2%	+50.4%	$5.61B	$189.76M	N/A	140	Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATAI) was last updated on 5/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Atai Beckley (ATAI) Competitors

ATAI vs. CNTA, MIRM, CGON, RYTM, and GRFS

How does Atai Beckley compare to Centessa Pharmaceuticals?

Summary

How does Atai Beckley compare to Mirum Pharmaceuticals?

Summary

How does Atai Beckley compare to CG Oncology?

Summary

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Summary

How does Atai Beckley compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Atai Beckley (ATAI) Competitors

ATAI vs. CNTA, MIRM, CGON, RYTM, and GRFS

How does Atai Beckley compare to Centessa Pharmaceuticals?

Does the media prefer CNTA or ATAI?

Is CNTA or ATAI more profitable?

Which has more volatility and risk, CNTA or ATAI?

Do insiders & institutionals hold more shares of CNTA or ATAI?

Which has better earnings and valuation, CNTA or ATAI?

Do analysts recommend CNTA or ATAI?

Summary

How does Atai Beckley compare to Mirum Pharmaceuticals?

Which has stronger valuation & earnings, ATAI or MIRM?

Does the media prefer ATAI or MIRM?

Do analysts recommend ATAI or MIRM?

Do institutionals & insiders believe in ATAI or MIRM?

Is ATAI or MIRM more profitable?

Which has more risk and volatility, ATAI or MIRM?

Summary

How does Atai Beckley compare to CG Oncology?

Which has higher valuation and earnings, ATAI or CGON?

Does the media prefer ATAI or CGON?

Is ATAI or CGON more profitable?

Do analysts prefer ATAI or CGON?

Do institutionals & insiders believe in ATAI or CGON?

Which has more volatility & risk, ATAI or CGON?

Summary

How does Atai Beckley compare to Rhythm Pharmaceuticals?

Does the media prefer ATAI or RYTM?

Is ATAI or RYTM more profitable?

Do analysts prefer ATAI or RYTM?

Which has higher valuation and earnings, ATAI or RYTM?

Which has more volatility & risk, ATAI or RYTM?

Do institutionals & insiders believe in ATAI or RYTM?

Summary

How does Atai Beckley compare to Grifols?

Does the media refer more to GRFS or ATAI?

Is GRFS or ATAI more profitable?

Do analysts recommend GRFS or ATAI?

Which has better earnings & valuation, GRFS or ATAI?

Which has more volatility & risk, GRFS or ATAI?

Do institutionals and insiders believe in GRFS or ATAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATAI vs. The Competition

Atai Beckley Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools